The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...

Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

Master the differences between NumPy arrays and Python lists with this clear guide. Learn when to use each, understand performance benefits, and see practical examples to write more efficient and ...

The ARAQYS-D3 mission by Dcubed will demonstrate the ability to manufacture a solar array 15 meters long in orbit. Credit: Dcubed BREMEN, Germany — German satellite component company Dcubed is moving ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

The simulation of quantum systems and the development of systems that can perform computations leveraging quantum mechanical effects rely on the ability to arrange atoms in specific patterns with high ...

Replimune Group is focused on developing immunotherapies using oncolytic viruses—engineered viruses that target and kill cancer cells while stimulating a patient’s immune response. Its lead product ...